CAU Scholar's Space: Kim, Eun Young

Detailed Information

Kim, Eun Young (김은영)

약학대학 (약학부)

Research Area

Tel 02-820-5791
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Metaanalysis:7||COVID19:7||metaanalysis:6||LCMS/MS:4||Trial registration:3||Pharmacokinetics:3||Rat:3||Rat plasma:3||SARSCoV2:3||Regulatory science:3||HPLCMS/MS:3||South Korea:3||survey:3||deep learning:2||Breast cancer:2||piperacillin/tazobactam:2||Importanceperformance analysis:2||Aceclofenac:2||ATMPs:2||topical corticosteroid:2||training project:2||Adverse drug reaction:2||Survey:2||Pharmacist:2||GPT4:2||7OSuccinyl macrolactin A:2||electrolyte disorder:2||vaccine:2||Macrolactin A:2||Duration of therapy:2||Bioavailability:2||randomized controlled trial:2||Epigenetic:2||resilience:2||Reporting quality:2||Vaccination:2||glycemic variability:2||clinical trials:2||Oncology:2||Metabolism:2||ADHD:2||Amisulpride:2||hypokalemia:2||Clinical trials:2||COVID19 hospitalization:1||COVID19 severity:1||COVID19 vaccine:1||CPEP:1||CPEPM:1||Cancer:1||Cardiopulmonary bypass:1||Cardiovascular disease:1||Casecontrol:1||Casecrossover:1||Cell storage:1||Cell therapy product:1||Cephalosporins:1||Cerebrovascular disease:1||ChatGPT3.5:1||Child:1||Cibotii Rhizoma:1||Claims database:1||Cleft palate and lip:1||Clinical pharmacist:1||Clinical trial:1||ClinicalTrials.gov:1||Clopidogrel resistance:1||Codonopsis pilosulae Radix:1||Combination strategies:1||Combined intravitreal antiviral treatment:1||Community pharmacy:1||Community pharmacy experiential practice:1||Comparative analysis:1||Computerbased test:1||Conjugated linoleic acid:1||Contrast media:1||Cost effectiveness:1||Crohn's disease:1||DNA mismatch repair:1||DTx:1||Dementia:1||Diacetyl sulfiaoxazole:1||Dietary supplement:1||Digital therapeutics:1||Dog plasma:1||Dosing regimen:1||Drug monitoring system:1||Drug prescriptions:1||Drug repositioning:1||Drug safety:1||Endpoint selection:1||Epidrugs:1||Etanercept:1||Examination:1||Expedited approval:1||Expedited processing system:1||Expedited program:1||FAERS database:1||FDA:1||FIP:1||Fall riskincreasing drugs:1||Fallrelated injuries:1||Fast Track:1||Fenofibric acid:1||Fentanyl PCA:1||Fish oil based fat emulsion:1||Fluoroquinolones:1||Food:1||GLP 1 agonist:1||GMP:1||GPT3.5:1||Gap:1||Gap analysis:1||Gender:1||Genetic variants:1||Glycemic control:1||Good Manufacturing Practice:1||HCT/Ps:1||HPLC:1||HPLCUV:1||Harmonization:1||Health Personnel:1||Healthcare professionals:1||Hemodialysis patient:1||Herbal medicines:1||Herbaldrugassociated ADR:1||High density lipoprotein:1||High maintenance dose:1||Highperformance liquid chromatography:1||Human:1||ICU:1||IMI:1||IRB:1||Immunizer:1||Inattention:1||Influenza:1||Influenza vaccination:1||Innovative CBT item types:1||Interim analysis:1||International Pharmaceutical Federation:1||Joint diseases:1||KPLE:1||Korea:1||Korean:1||Korean Medicine:1||Korean Pharmacist Licensing Examination:1||Licensure:1||Lipids:1||Lipoprotein:1||Lobetyol:1||Lobetyolin:1||Lung cancer:1||MFDS:1||MRSA:1||Magnesium:1||Mandible:1||Mesupron:1||Metabolic syndrome:1||Mice:1||Misconduct:1||Multidisciplinary team:1||Multiregional clinical trial:1||Mupirocin:1||N1acetyl sulfisoxazole:1||N4acetyl sulfisoxazole:1||NHIS database:1||NSAIDs:1||National R&D projects:1||National licensing examination:1||Network metaanalysis:1||Nonsmallcell lung cancer:1||Nurses:1||Nursing:1||Obesity:1||Older:1||Oleanolic acid:1||Operating rooms:1||Orthotopolin riboside:1||Outcome measures:1||PD1/PDL1 inhibitor:1||PK/PD modeling:1||PN associated liver disease:1||Panax ginseng:1||Panduratin A:1||Parity:1||Patient on hemodialysis:1||Pediatrics:1||Pharmacokinetic modeling:1||Pharmaconutrition:1||Pharmacopoeia:1||Pharmacotherapeutic implications:1||Pharmacovigilance:1||Phase II trials:1||Phase II/phase III:1||Phase III trials:1||Pneumonia:1||Polycaprolactone:1||Polymorphism:1||Postoperative arrhythmia:1||Preceptor role:1||Precision medicine:1||Preterm infants:1||Primary outcomes:1||Progressive outer retinal necrosis:1||Protocol disclosure:1||Public Health:1||Publication:1||Publication bias:1||Qualitative research:1||Quality control:1||Questionnaire:1||Rabbit:1||Randomized controlled trial:1||Randomized controlled trials:1||Randomized trials:1||Regulatory system:1||Reporting:1||Research design:1||Retraction:1||Retraction of Publication:1||SGLT2 inhibitor:1||SPIN:1||Secondary outcomes:1||Side effects:1||Soybean oil based fat emulsion:1||Stability:1||Steroid phobia:1||Students:1||Sulfisoxazole:1||Systematic review:1||Systemic exposure:1||Tangshenoside I:1||Topical ocular:1||Topical steroid:1||Topical steroid prescription:1||Trial transparency:1||Tumblr:1||Twitter:1||Type 2 diabetes:1||Type 2 diabetes mellitus:1||UPLC:1||UV detection:1||Uridine:1||Vaccine hesitation:1||Withdrawal:1||a systematic review:1||academic gap:1||acceptance:1||adolescent:1||advanced therapy medicinal products:1||adverse drug event:1||adverse drug events:1||adverse drug reactions:1||adverse effect:1||adverse event:1||adverse reactions:1||agranulocytosis:1||ambulatory analgesics:1||ambulatory setting:1||amyloid:1||animal models:1||anosmia:1||antidepressants:1||antioxidative activity:1||appropriateness of prescription:1||artificial intelligence:1||attentiondeficit/hyperactivity disorder:1||bioethical oversight:1||biomarkers:1||caffeine:1||cancer drugs:1||cerebrospinal fluid:1||child:1||clinical trial:1||communication competence:1||concept development:1||critical care pharmacist:1||critical thinking disposition:1||crossreactivity:1||customized implant:1||data mining:1||depression:1||diabetes mellitus:1||digital pathology:1||dipeptidylpeptidase 4 inhibitor:1||disproportionality analysis:1||distraction osteogenesis:1||drug–drug interaction:1||drug compendia:1||drug development:1||drug monograph:1||dyslipidemias:1||education and training:1||emerging infectious disease:1||endpoint:1||ethical oversight system:1||experiential education:1||fentanyl:1||fentanyl TTS:1||fixeddose combination drugs:1||forms:1||gap analysis:1||gastric esophageal cancer:1||global vaccine organization:1||glucagonlike peptide 1 agonist:1||good manufacturing practice:1||harm:1||health status:1||hospital pharmacy preceptor:1||human subjects & derivatives:1||hybrid model:1||illicit online drug sales:1||immunogenicity:1||incidence:1||inflammatory bowel disease:1||influenza:1||innovative medicines initiative:1||institutional review board:1||intensive care unit:1||irisdichototins E & F epimeric mixture:1||knowledge:1||leadership:1||length of stay:1||machine learning:1||marketing authorization:1||maxillary advancement:1||medication errors:1||methimazole:1||methodological rigour:1||methylphenidate:1||microsatellite instability:1||multilateral approaches:1||myocardial infarction:1||national R&D projects:1||network metaanalysis:1||neuroinvasion:1||nonsteroidal antiinflammatory drugs:1||nonmedical use:1||nonsignificant primary outcome:1||observational study:1||onitin4OβDglucopyranoside:1||opioids:1||pandemic:1||patterns and trends:1||penicillins:1||perception:1||percutaneous absorption:1||pharmaceutical services:1||pharmacokinetics:1||pharmacotherapy:1||pharmacovigilance:1||pharmacovigilance study:1||pharmacy students:1||postoperative pain management:1||preceptorship:1||preclinical studies:1||pregnant women:1||prescription patterns:1||primary metabolites:1||problemsolving ability:1||propylthiouracil:1||prospective:1||prothrombin time:1||protocatechuic acid:1||psychiatric disorder:1||public awareness:1||public knowledge:1||rapid onset opioids:1||rats:1||region:1||regulation:1||regulatory science education:1||regulatory system:1||reproducibility of results:1||risk factor:1||rivaroxaban:1||safety:1||safety evaluation:1||satellite pharmacy:1||satisfaction:1||scale development:1||serious adverse events:1||seropositivity:1||social media:1||social network services:1||sodiumglucose cotransporter 2 inhibitor:1||stress:1||sulfonamide allergy and hypersensitivity:1||sulfonamide medications:1||systematic review:1||tau:1||terpinyl acetate:1||the Korea National Health Insurance Service database:1||therapeutic duplication:1||transitional program:1||treatment outcome:1||ulcerative colitis:1||umbrella review:1||urological disease:1||utility pattern:1||vaccination:1||vaccine platform technologies:1||vaccine support program:1||vancomycin:1||ventilatorassociated pneumonia:1||verapamil:1||virtual surgical planning:1||간호사:1||돌봄:1||질적연구:1||2'Hydroxy3', 4'methylenedioxy3,4,5trimethoxychalcone:1||치매:1||3OAcetyloleanolic acid:1||3Dprinting:1||4 'Hydroxydiclofenac:1||4 'Hydroxydiclofenac, Diclofenac:1||ACE statement:1||ADR:1||ADR reporting system:1||AML/MDS:1||ANCAassociated vasculitis:1||Absolute bioavailability:1||Accelerated Approval:1||Acute coronary syndrome:1||Adaptive:1||Adaptive design:1||Addon RCT design:1||Advanced Therapy Medicinal Products:1||Advanced breast cancer:1||Advanced stage:1||Advanced therapy medicinal products:1||Adverse Drug Reaction:1||Adverse effects:1||Advocate:1||Aerosolized colistin:1||Allogeneic cell therapy product:1||Alveolar ridge augmentation:1||Alzheimer's disease:1||Alzheimer’s disease:1||Amoxicillin:1||Amoxicillinpotassium:1||Ankylosing spondylitis:1||Anosmia:1||Antibacterial agents:1||Antithyroid drugs:1||Autologous chondrocytes:1||Awareness:1||Bias:1||Bioactive glass:1||Bone mineral density:1||Breakthrough cancer pain:1||Creactive protein:1||CAPE:1||CD28:1||CONSORT for Abstracts:1||

RSS_1.0 RSS_2.0 ATOM_1.0

84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE